Neuronetics Inc
NASDAQ:STIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuronetics Inc
Cash from Operating Activities
Neuronetics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuronetics Inc
NASDAQ:STIM
|
Cash from Operating Activities
-$20.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$4.5B
|
CAGR 3-Years
44%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$9.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
What is Neuronetics Inc's Cash from Operating Activities?
Cash from Operating Activities
-20.4m
USD
Based on the financial report for Dec 31, 2025, Neuronetics Inc's Cash from Operating Activities amounts to -20.4m USD.
What is Neuronetics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
6%
Over the last year, the Cash from Operating Activities growth was 34%. The average annual Cash from Operating Activities growth rates for Neuronetics Inc have been 13% over the past three years , 6% over the past five years .
